2021 Bio-enzyme Application Explorer Summit held in Chengdu

0

The event focuses on innovation and development of biochemical pharmaceuticals

CHENGDU, China, Oct. 22, 2021 / PRNewswire / – The biochemical pharmaceutical industry faces unprecedented opportunities and challenges with the changing economic and political environment in China and abroad. At October 15, the first Bio-enzyme Application Explorer Summit was held in Chengdu under the theme “Dare to dream, dare to take responsibility”. The summit was hosted by Sichuan Deebiotech Co., Ltd., a global expert in bioenzyme production and R&D, with the aim of promoting the innovative development of the biochemical pharmaceutical industry.

Summit Dialogue Sessions at the First Bio-enzyme Application Explorer Summit

The summit brought together a number of big names, including Wei Yuquan, academician of the Chinese Academy of Sciences and former vice president of Sichuan University; Professor Wang Hongguang, Director of the International Center for Bioeconomics, Tsinghua University and Special Guest Expert on the CPPCC National Committee; Professor Yu rong, director of the Department of Biotechnology and Pharmacology and thesis director of West China Pharmacological faculty, Sichuan University; Dr Luo Xia, Director of the Institute of Mycological Herbs, Sichuan Academy of Traditional Chinese Medicine; and Dr. Tang Can, graduate student tutor at Chengdu Medical College; as well as representatives of food companies such as Muyuan Foods and Longda Food, bioenzyme preparation companies such as Livzon Pharm, Shunsheng Pharmaceutical, Livu Pharmaceutical, Tongde Pharmacy and Sichuan Deebiotech, and securities companies of Dongguan Securities, Zheshang Securities , PingAn Securities and Dongxing Securities, to discuss industry development plans.

New opportunities and challenges coexist as the industry enters a new era

Brands 2021 the first year of from China “14th five-year plan”, which emphasizes innovation-driven development. The pharmaceutical industry has deployed five-year plans for different segments, which, coupled with the implementation of new medical policies and environmental protection policies, are bringing the pharmaceutical industry a new wave of industrial transformation and modernization opportunities.

The biochemical pharmaceutical sector, as a branch of the biopharmaceutical industry, started in China in the 1970s. It is a booming and growing force in from China pharmaceutical industry, and has become one of the top three pharmaceutical industries in China.

“Enzyme preparations are also an important part of biological products,” said Wei Yuquan, academician of the Chinese Academy of Sciences and former vice president of Sichuan University. “There are over two thousand types of enzymes in our body. It really is a great machine. Therefore, developing enzymes as a medicine shows great promise.”

However, compared to foreign countries, from China the biochemical pharmaceutical and enzyme preparation industries have a late start and have a weak base. In addition, industries suffer from insufficient investment in R&D, weak application and product development capabilities, inadequate technical innovation capabilities and the need to improve product quality, which severely restricts production. biochemical industry to seize development opportunities in the new era.

“The community of bioenzymes in China in our country is not broad-minded enough compared to foreign countries, both in terms of product quality and variety development, ”said Dr. Tang Can, graduate student tutor at Chengdu Medical College. “Some countries have produced many products that we dare to. not imagine. There may therefore be a certain gap between China and foreign countries in terms of the speed of development and quality of bio-enzymes. “

Effectively promote industrial transformation and modernization by setting up an alliance and a fund

For this reason, the first Bio-enzyme Application Explorer Summit organized by Sichuan Deebiotech is of great importance to stimulate the development of biochemical pharmaceutical industry.

On the one hand, the quality and safety of pharmaceuticals is not only linked to the survival of patients and pharmaceutical companies, but also to the rise and fall of the pharmaceutical industry. Ensuring the quality and safety of pharmaceutical products requires the concerted efforts of the entire industry. Therefore, Sichuan Deebiotech, partnering with Muyuan Foods, Longda Food in Liaocheng, Livzon Pharm in Shanghai, Shunsheng Pharmaceutical at Sichuan, Tongde Pharmacy at Chengdu and Livu Pharmaceutical at Henan, has set up the “Quality and Safety Alliance of the Bio-enzymes Industrial Chain”. Upstream, middle and downstream actors across the entire industrial chain have all vowed to work together and do their best to protect patient drug safety. of raw material and manufacturing outlook.

“The initial goal of establishing the Quality and Safety Alliance is to ensure and improve the quality of pharmaceuticals and to ensure the safe use of pharmaceuticals by patients,” said Zhang Ge, president of Sichuan Deebiotech. “Then the Alliance plans to do four things. First, it will establish a benchmark of quality, which will allow everyone to know what is good; second, we will develop a quality convention that we will all abide by, to strengthen self-discipline within the industry; third, we still hope to expand the Alliance, improve communication between member companies; and fourth, we hope that Alliance members can act as representatives of industry to achieve certain achievements. “

On the other hand, Sichuan Deebiotech has set up the “Bio-enzyme Innovation and Application R&D Fund “with a starting capital of 10 million yuan, with the aim of promoting the development of the biochemical pharmaceutical industry by China, improve technologies and cultivate innovative talents in the biochemical industry. Outstanding scientific researchers and R&D teams targeting biological enzyme product development and product improvement and innovation are eligible to apply for the fund. This fund aims to encourage enterprises, universities and research institutes to engage in innovative research and development of biochemical products and technologies, thus comprehensively improving the independent innovation capacity of Chinese biochemical enterprises and their basic competitiveness on the international scene.

Gather the wisdom to build a new future led by leading companies

The transformation and development of the industry requires not only the leadership of leading companies, but also the support and cooperation of the entire industrial chain.

Summit organizer Sichuan Deebiotech is a leading company in the global bioenzyme industry and the largest pancreatin supplier on the world market, with a market share of over 30% in pepsin and trypsin-chymotrypsin markets. It is the only supplier of elastase, pepsin in clear solution and pancreatin rich in lipase in China. The company has passed the GMP certifications in the EU and China since 2005, and has the production technologies of high activity, high purity and high stability bioenzymes. Its products have been exported to Europe, United States, Japan and Korea for more than 20 years and marketed in 30 countries and regions worldwide.

As a veteran who has worked in the bioenzyme industry for nearly 30 years, Zhang Ge, President of Sichuan Deebiotech, understands the close links between industry development and industry-university-research cooperation. “The work we have done on the application and development of medicinal bioenzymes is far from sufficient, especially for those of natural origin,” said Zhang. “Therefore, opening up a wider space for the application of pharmaceutical bio-enzymes is the key to the development of bio-enzyme companies. We are committed to putting into practice the industrial concept of knowledge unit and action, and to create a platform for the whole bio-enzymes industry to develop a wider space for bio-enzyme applications. Such a platform, industry experts, academics and entrepreneurs can exchange ideas, discuss topics and cooperate to jointly promote the innovative development and application of bio-enzymes. “

On summit day, Deebiotech (Chengdu) Co., Ltd. has been successfully completed, in order to continue industry-university-research cooperation and the transformation of research results to expand the applications of bio-enzymes. The company serves as an open window and development center for Deebiotech, with a primary focus on promoting the implementation of applied research and development of bio-enzymes. Going forward, Deebiotech (Chengdu) will bring together more excellent professionals and R&D teams from China and abroad to jointly support the organic products industry in China to seize opportunities and meet challenges, and create a better future for the industry.

The Bio-enzyme Application Explorer Summit is not only a great event for pioneers and builders in the industry, but also a landmark event for Deebiotech to continue its deep expansion in the field of bio-enzymes. “As a pharmaceutical company, we have a bigger dream, which is to say that we hope to let bio-enzymes play their important role for the benefit of human beings, and I think that is also the dream. of the entire bio-enzyme industry, ”Zhang said.

Media contact:

Contact: Selina liu
Email: [email protected]
Website: http://www.deebiotech.com

View original content to download multimedia:

SOURCE Sichuan Deebiotech Corp., Ltd


Source link

Share.

Leave A Reply